ASHP Injectable Drug Information | Mobile App & Web

Based on 23rd edition, American Society of Health-System Pharmacists the most comprehensive reference on injectable drug data. Current 2023 edition features 18 new monographs and nearly 200 new references for a total of over 24,000 total compatibility pairs.

Includes 1-year online access with WebView.

Editor(s): ASHP

Publisher: American Society of Health-System Pharmacists

2023 Edition

For more than 40 years ASHP has published the most trusted resource for injectable drug information. Our new ASHP® Injectable Drug InformationTM now delivers the same high-quality content that you can expect from ASHP with even MORE of the information you need to make decisive patient care decisions.

ASHP® Injectable Drug InformationTM 2023 now comes complete with 2 years of digital interactive access and a print edition to ensure you have constant, uninterrupted access. The digital content is interactive, mobile, and updated quarterly. Includes monographs to Extended Stability for Parenteral Drugs, forming a single, comprehensive resource on injectable drug information.

Backed by quality, peer-reviewed published literature and authored under the editorial authority of ASHP, it is a must-have resource for every pharmacy.

Key Features

  • Quick data search for 358 drugs
  • 417 monographs on parenteral drugs available in the United States and in other countries
  • Monographs cross-referenced with American Society of Health-System Pharmacists (AHFS) Drug Information through AHFS classification numbers
  • More than 500 revisions to existing monographs (affecting nearly 60% of the existing monographs) have been accomplished to update information on stability, compatibility, and safety (e.g., Food and Drug Administration [FDA] MedWatch alerts) and to provide more specific referencing of manufacturer information and other enhancements to the more than 24,100 compatibility pairs contained in ASHP® Injectable Drug Information™ 2023.
  • How to prepare, store and administer drugs
  • Information accumulated from 3,603 references
  • Quick identification of drug compatibility with easy to understand icons
  • Drugs listed alphabetically by generic name for efficient searching, with brand names also listed
  • Tabulated results from primary research on the compatibility of the listed drug with infusion solutions and other drugs
  • Four compatibility tables are provided for each drug: solution, additive, syringe, and Y-site
  • Storage requirements and general stability information, including pH, freezing, exposure to light, sorption and filtration characteristics, and repackaging information
  • Key product data including common sizes, strengths, volumes, and forms in which the drug is supplied. Also includes pH, osmotic value, and other important product information
  • Parenteral Drugs by Caryn Bing and Anna Nowobilski-Vasilios. This extended stability information is specifically designed for use in home and other infusion practices

INFO FOR REFERENCE:

ASHP® Injectable Drug Information™ 2023 includes 18 new monographs, bringing the total in this edition to 417 monographs on parenteral drugs available in the United States and in other countries. In addition, more than 500 revisions to existing monographs (affecting nearly 60% of the existing monographs) have been accomplished to update information on stability, compatibility, and safety (e.g., Food and Drug Administration [FDA] MedWatch alerts) and to provide more specific referencing of manufacturer information and other enhancements to the more than 24,100 compatibility pairs contained in ASHP® Injectable Drug Information™ 2023. The information cited throughout the text has been compiled from 3603 references, including 195 new to this edition. Because information from pharmaceutical manufacturers had not been uniquely cited until the 18th edition, the number of unique references supporting ASHP® Injectable Drug Information™ 2023 information actually greatly exceeds this number. While primary, peer-reviewed literature remains a major source of compatibility and stability information, ongoing efforts are underway to provide increased specificity of references to the pharmaceutics research of drug manufacturers. Other relevant information and pertinent study details supplied by corresponding authors of the published literature also have been incorporated when available.


ISBN 10: 1585286834

ISBN 13: 9781585286836

{hbinjdrg21:3530}